Scarica l'app Stockscreener
38.58
0.49%
-0.19
Dopo l'orario di chiusura:
38.55
-0.03
-0.08%
Precedente Chiudi:
$38.77
Aprire:
$38.93
Volume 24 ore:
480.44K
Relative Volume:
1.53
Capitalizzazione di mercato:
$1.22B
Reddito:
$566.77M
Utile/perdita netta:
$48.16M
Rapporto P/E:
32.42
EPS:
1.19
Flusso di cassa netto:
$274.29M
1 W Prestazione:
+2.52%
1M Prestazione:
+21.40%
6M Prestazione:
+36.08%
1 anno Prestazione:
+2.72%
Intervallo 1D:
$38.29
$39.06
Intervallo di 1 settimana:
$37.29
$39.95
Portata 52W:
$23.23
$42.29
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Nome
Collegium Pharmaceutical Inc
Settore
Telefono
781-713-3699
Indirizzo
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Confronta COLL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
38.58 | 1.20B | 566.77M | 48.16M | 274.29M | 1.19 |
|
ZTS
Zoetis Inc
|
154.79 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.88 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.63 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.15 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
309.22 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | Needham | Hold → Buy |
| 2024-07-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-05-10 | Downgrade | Needham | Buy → Hold |
| 2024-05-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-08-25 | Reiterato | Needham | Buy |
| 2023-05-02 | Ripresa | Jefferies | Buy |
| 2022-08-08 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-14 | Iniziato | BWS Financial | Sell |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-02-19 | Ripresa | Jefferies | Buy |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-03 | Ripresa | H.C. Wainwright | Buy |
| 2019-04-12 | Ripresa | Janney | Buy |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2018-02-07 | Reiterato | Needham | Buy |
| 2017-12-05 | Reiterato | Needham | Buy |
| 2017-09-11 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-09-13 | Iniziato | Gabelli & Co | Buy |
| 2015-06-01 | Iniziato | Jefferies | Buy |
| 2015-06-01 | Iniziato | Needham | Buy |
| 2015-06-01 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
RSI Suggests Rebound May Be Near in Collegium Pharmaceutical Inc.July 2025 Big Picture & Growth Oriented Trade Recommendations - beatles.ru
Developing predictive dashboards with Collegium Pharmaceutical Inc. dataMarket Trend Review & Free Technical Confirmation Trade Alerts - Newser
What indicators show strength in Collegium Pharmaceutical Inc.July 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Will Collegium Pharmaceutical Inc. stock go up soon2025 Trading Recap & Low Risk High Reward Ideas - Newser
Collegium Pharmaceutical Inc. stock chart pattern explainedMarket Growth Summary & AI Forecast for Swing Trade Picks - Newser
Full technical analysis of Collegium Pharmaceutical Inc. stock2025 Investor Takeaways & Weekly Momentum Picks - Newser
What MACD signals say about Collegium Pharmaceutical Inc.Trade Risk Report & Free Long-Term Investment Growth Plans - Newser
Trend analysis for Collegium Pharmaceutical Inc. this week2025 EndofYear Setup & Daily Risk Controlled Trade Plans - Newser
Is Collegium Pharmaceutical Inc. stock poised for growthPortfolio Value Summary & High Conviction Investment Ideas - Newser
Collegium Pharmaceutical Inc. stock prediction for this weekPortfolio Risk Summary & Technical Entry and Exit Alerts - Newser
Is Collegium Pharmaceutical Inc. still worth holding after the dipEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Risk adjusted return profile for Collegium Pharmaceutical Inc. analyzedMarket Sentiment Summary & Fast Momentum Stock Entry Tips - Newser
Technical analysis overview for Collegium Pharmaceutical Inc. stockCPI Data & Free Community Supported Trade Ideas - Newser
Is this a good reentry point in Collegium Pharmaceutical Inc.Rate Hike & Weekly Setup with ROI Potential - Newser
Backtesting results for Collegium Pharmaceutical Inc. trading strategiesInsider Buying & Free Technical Pattern Based Buy Signals - Newser
Maryland State Retirement & Pension System Reduces Position in Collegium Pharmaceutical, Inc. $COLL - Defense World
Sector ETF performance correlation with Collegium Pharmaceutical Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - Newser
How to build a dashboard for Collegium Pharmaceutical Inc. stockWeekly Stock Recap & High Return Stock Watch Alerts - Newser
Rubric Capital Management Sells 25,000 Collegium Pharmaceutical Shares for $946,250 - AInvest
How to use a screener to detect Collegium Pharmaceutical Inc. breakoutsJuly 2025 Fed Impact & Free Long-Term Investment Growth Plans - Newser
Multi asset correlation models including Collegium Pharmaceutical Inc.Earnings Risk Report & Real-Time Volume Spike Alerts - Newser
What data driven models say about Collegium Pharmaceutical Inc.’s future2025 Key Highlights & Risk Controlled Stock Alerts - Newser
Can momentum traders help lift Collegium Pharmaceutical Inc.July 2025 Technicals & Verified Momentum Stock Alerts - Newser
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by HC Wainwright to "Strong-Buy" Rating - MarketBeat
Is Collegium Pharmaceutical's (COLL) Revenue Guidance and Buyback Balancing Short-Term Results With Long-Term Value? - simplywall.st
Major Shareholder Offloads Thousands of Collegium Pharmaceutical Shares! - TipRanks
Collegium pharma EVP Dreyer sells $184,880 in stock - Investing.com
Collegium pharma EVP Dreyer sells $184,880 in stock By Investing.com - Investing.com Australia
Collegium Pharmaceutical EVP Scott Dreyer Sells 4,861 Shares, Buys 4,861 at $38.03/Share. - AInvest
Have Collegium Pharmaceutical Insiders Been Selling Stock? - 富途牛牛
Published on: 2025-08-16 02:26:13 - thegnnews.com
We Think You Can Look Beyond Collegium Pharmaceutical's (NASDAQ:COLL) Lackluster Earnings - Yahoo Finance
How Collegium Pharmaceutical Inc. stock performs during market volatility2025 Trading Recap & Safe Capital Growth Plans - beatles.ru
Collegium Pharmaceutical Inc. Nearing Breakout Level After BounceJuly 2025 Gainers & Safe Entry Trade Reports - beatles.ru
The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call - Yahoo Finance
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” at HC Wainwright - Defense World
Can Collegium Pharmaceutical Inc. recover in the next quarterJuly 2025 Reactions & Safe Capital Growth Plans - Newser
Quant Tools Rank Collegium Pharmaceutical Inc. as High Risk High RewardEarnings Beat & Short-Term Trading Opportunity Alerts - newsyoung.net
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics - msn.com
Collegium Pharmaceutical Inc. Bounces Off Moving Average SupportQuarterly Trade Summary & Long Hold Capital Preservation Tips - sundaytimes.kr
Published on: 2025-08-13 16:47:11 - beatles.ru
IBD Rating Upgrades: Collegium Pharmaceutical Flashes Improved Relative Price Strength - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World
3 Profitable Stocks We Think Twice About - Yahoo Finance
Collegium Pharmaceutical Q2 Earnings: Revenue Beats Estimates, Margin Pressure from Investments - AInvest
COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure - Yahoo Finance
Collegium Pharmaceutical Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
Collegium Pharmaceutical Earns Membership In 95-Plus Composite Rating Club - MSN
H.C. Wainwright assumes coverage on Collegium Pharmaceutical stock with Buy rating - Investing.com Canada
Collegium Pharmaceutical (COLL) Is Up 16.2% After Raising 2025 Revenue Guidance on Strong Q2 Results - simplywall.st
Collegium Pharmaceutical Inc Azioni (COLL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Collegium Pharmaceutical Inc Azioni (COLL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dreyer Scott | EVP & Chief Commercial Officer |
Aug 18 '25 |
Sale |
38.21 |
16,389 |
626,171 |
103,613 |
| SANTINI GINO | Director |
Aug 15 '25 |
Option Exercise |
13.45 |
15,000 |
201,750 |
100,447 |
| SANTINI GINO | Director |
Aug 15 '25 |
Sale |
37.19 |
5,405 |
201,018 |
95,042 |
0.07%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):